经动脉介入治疗肝细胞癌伴腹膜转移的安全性和有效性。
Safety and efficacy of transarterial interventional therapy for treatment of hepatocellular carcinoma with peritoneal metastases.
作者信息
Duan Feng, Bai Yanhua, Cui Li, Li Xiaohui, Yan Jieyu
机构信息
Department of Interventional Radiology, The General Hospital of Chinese People's Liberation Army, Beijing, China.
出版信息
J Cancer Res Ther. 2018;14(7):1563-1566. doi: 10.4103/jcrt.JCRT_984_17.
PURPOSE
The aim of this study was to evaluate the safety and efficacy of transarterial interventional therapy for the treatment of hepatocellular carcinoma (HCC) patient with peritoneal metastases.
MATERIALS AND METHODS
A total of 7 HCC patients with peritoneal metastases were treated by interventional therapy. Combined treatment with transarterial chemoembolization for intrahepatic lesions and transarterial embolization for peritoneal metastases was performed through hepatic artery, gastroduodenal artery, and superior mesenteric artery.
RESULTS
Treatment resulted in an objective response of 85.7% Modified Response Evaluation Criteria in Solid Tumors. No severe adverse effects were observed.
CONCLUSIONS
Transarterial interventional therapy can be performed safely and may improve the prognosis of HCC patients with peritoneal metastases.
目的
本研究旨在评估经动脉介入治疗对伴有腹膜转移的肝细胞癌（HCC）患者的安全性和有效性。
材料与方法
共有7例伴有腹膜转移的HCC患者接受了介入治疗。通过肝动脉、胃十二指肠动脉和肠系膜上动脉，对肝内病变进行经动脉化疗栓塞，对腹膜转移灶进行经动脉栓塞的联合治疗。
结果
根据实体瘤改良反应评估标准，治疗产生了85.7%的客观缓解率。未观察到严重不良反应。
结论
经动脉介入治疗可安全进行，并可能改善伴有腹膜转移的HCC患者的预后。
Zotero 插件